Samsung EpiS (KRX:0126Z0) said its unit, Samsung Bioepis, signed a development and commercialization deal with South Korean biotechnology company IntoCell for its cancer therapy candidate SBE303, targeting Nectin-4 protein-expressing solid tumors.
The deal finalized on Wednesday is part of a joint research pact signed in December 2023 to discover up to five antibody-drug conjugate candidates, according to a same-day filing with the Korean Exchange.
The new deal secures rights to SBE303, currently being evaluated in a global Phase 1 clinical trial targeting 149 patients, with financial terms of the agreement yet to be disclosed.
The contract includes development milestone payments tied to clinical progress, regulatory approvals, commercialization milestones, and sales-based royalties.